Almazov National Medical Research Centre
Saint Petersburg, Russia
Location status: Recruiting
NCT Number: NCT06288633
This is a multicenter prospective randomized blind controlled trial with a sham procedure group of the efficacy and safety of cardioneuroablation as a method of treating symptomatic bradycardia without a permanent pacemaker implantation
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Saint Petersburg, Russia
Location status: Recruiting
Catheter ablation is a common treatment for cardiac arrhythmias. Some patients with AF ablation or AVNRT experience acceleration of sinus rhythm, the most likely cause of which is modification of autonomic tone caused by inadvertent damage to intramural autonomic ganglia and fibers. Intentional damage to these plexuses has become known as cardioneuroablation (CNA) and is currently used in patients with tachycardia-bradycardia syndrome, vegetatively caused sinus node dysfunction and atrioventricular conduction disorders, vasovagal syncopal conditions developing in a cardioinhibitory type.
It is suggested that in some patients CNA may become an alternative to permanent pacemaker for the treatment of symptomatic bradyarrhythmias.
This is a multicentre randomised clinical study evaluating the efficacy of cardioneuroablation for severe bradycardia due to sinus node dysfunction and/or atrioventricular nide dysfunction versus a sham procedure.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(1.1.) Symptomatic sinus bradycardia or bradycardia due to atrioventricular blockade, including transient.
(1.2.) Severe asymptomatic sinus bradycardia with a rhythm frequency of <30 beats/min.
(1.3.) Transient atrioventricular block of II-III degree or permanent block of II degree.
(1.4.) Repeated fainting or pre-fainting states with a proven association with bradycardia (without injury).
(1.5.) Rhythm pauses >6 seconds.
In combination with the following two criteria:
(2.1.) Increase in sinus rhythm frequency ≥25% or >90 beats/min. (2.2.) The transition of atrioventricular blockade of the II-III degree to the 1st degree or complete normalization of atrioventricular conduction at the sinus rhythm.
Exclusion criteria
Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated.
Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system.
During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size.
Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.
Time frame: 12 months post procedure
Once there is a recurrence of documented symptomatic bradycardia, a permanent pacemaker implantation is considered
Time frame: 30 days post procedure
Cardiac tamponade, pericardial effusion >10 mm, esophageal damage, stroke or transient ischemic event, severe groin hematoma (hemoglobin level drop >20%), atriovenous fistula in the groin
Time frame: 12 months post procedure
As detected by ECG monitoring
Time frame: 12 months post procedure
As detected by ECG monitoring
Time frame: 12 months post procedure
As detected by ECG monitoring
Time frame: 12 months post procedure
Tilt-testing
Time frame: 30 days post procedure
As detected by ECG monitoring, defined as daytime mean heart rate >100 bpm
Time frame: 24 months post procedure
Once there is a recurrence of documented symptomatic bradycardia, a permanent pacemaker implantation is considered
Contact information is provided by the study sponsor or research team.
Aleksandr Vakhrushev, PhD
CONTACT
Evgeny Mikhaylov, PhD, Prof.
CONTACT
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Other
Cardioneuroablation for Bradyarrhythmia (Sinus Node and Atrioventricular Node Dysfunction): a Sham-controlled Randomised Multicentre Trial
Acronym: CARDIOBOOST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05887323
Arrhythmia, Sinus, Arrhythmias, Cardiac
Jonesboro, Arkansas, United States
View Trial DetailsNCT03719040
Arrhythmia, Sinus, Arrhythmias, Cardiac
Huntsville, Alabama, United States
View Trial DetailsNCT07671898
Arrhythmia, Sinus, Arrhythmias, Cardiac
Tomsk, Tomsk Oblast, Russia
View Trial DetailsNCT04075084
Arrhythmias, Cardiac, Atrial Fibrillation
Adelaide, Australia
View Trial Details